NSE: CIPLA | BSE: 500087

Falling Comet

Download real time

1463.05 47.45 (3.35%)

2.4M NSE+BSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

118,158.4

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

US FDA Approval

Cipla gets US FDA nod for ANDA of Paclitaxel injectable suspension with a market size of $88 bn See details

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

12 Aug 2023, 12:00AM

1463.05

3.35%

Pick of the Week:14 AUG 2023

Buy: Cipla Ltd.

Target

Axis Direct

Recommendation: We recommend a BUY on the stock with a Target Price of Rs 1,380/share

Cipla Ltd. is trading below its 100 day SMA of 1467.3

Cipla Ltd.

28 Jul 2023

1463.05

3.35%

Strong quarterly performance; gRevlimid drives growth

Buy: Cipla Ltd.

Target

KRChoksey

The revenue from the North America segment was USD 222 million, experiencing a 9% sequential growth, led by improved market share in its peptide products such as gSomatuline and higher contributions from gRevlimid.

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

27 Jul 2023

1463.05

3.35%

Cipla Limited

Results Update: Cipla Ltd.

SMC online

Cipla Ltd. is trading below its 100 day SMA of 1467.3

Cipla Ltd.

27 Jul 2023

1463.05

3.35%

Cipla (BUY): Strong growth coupled with margin expansion

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Q1 EBITDA/PAT beat estimates by 7%/16% on the back of growth in North America and One India

Cipla Ltd. is trading below its 100 day SMA of 1467.3

Cipla Ltd.

27 Jul 2023

1463.05

3.35%

Margin accretion story unfolding...

Buy: Cipla Ltd.

Recommendation Target

ICICI Securities Limited

Cipla’s Q1FY24 performance was a beat on all fronts, driven primarily by swift uptick in the core markets of India (up 12%) and US (up ~9% QoQ). gRevlimid continues to be an important product in the US, though traction in Q1 was driven by volume growth in the base portfolio.

Cipla Ltd. is trading below its 100 day SMA of 1467.3

Cipla Ltd.

27 Jul 2023

1463.05

3.35%

Result Update:Cipla

Buy: Cipla Ltd.

Target

Axis Direct

We have BUY on Cipla

Cipla Ltd. is trading above its 50 day SMA of 1459.2

Cipla Ltd.

26 Jul 2023

1463.05

3.35%

CIPLA LTD.

Buy: Cipla Ltd.

Target

Prabhudas Lilladhar

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

17 May 2023

1463.05

3.35%

CIPLA LTD

Buy: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

17 May 2023

1463.05

3.35%

Muted performance due to drop in India business revenue

Buy: Cipla Ltd.

Recommendation Target

KRChoksey

The company reported a decline in revenue by 1.3% QoQ (+9.1% YoY) to INR 57,393 Mn in Q4FY23. The drop in revenue was mainly attributable to the decline in India business revenue by 12.8% QoQ (+2.5% YOY) to INR 22,383 Mn (39% of revenue). Although on Ex- COVID basis, the Indian business grew at a healthy rate of 16% owing to increase in demand in flu season. with India business, the company witnessed a robust growth across branded prescription, trade generics and consumer health in FY23.